Oct 05, 2020 8:30am EDT Development of Next-Generation Drugs to Inhibit Ravages of Chronic Inflammation
Oct 01, 2020 8:30am EDT Groundbreaking Studies Offer Hope for Unmet Medical Needs in Inflammatory Disease
Jul 26, 2019 9:00am EDT KBL Merger Corp. IV SPAC Signs Definitive Business Combination Agreement to Acquire CannBioRx Life Sciences Corp.
May 14, 2019 8:00am EDT KBL Merger Corp. IV SPAC Announces Non-Binding Term Sheet to Acquire CannBioRx Life Sciences Corp. and its Three Interactive Programs
Jun 23, 2017 4:32pm EDT KBL Merger Corp. IV Announces Closing of Underwriters' Over-Allotment Option in Full in Connection with its Initial Public Offering and Separate Trading of its Common Stock, Rights and Warrants, Commencing June 27, 2017
Jun 01, 2017 8:21pm EDT KBL Merger Corp. IV Announces Pricing of $100 Million Initial Public Offering
